Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
RadNet Q4 2025 Earnings Call - Gleamer deal crowns DeepHealth largest radiology AI provider, sets ARR target ~$140M in 2026
RadNet closed a record Q4: revenue $547.7M, up 14.8%, and Adjusted EBITDA $87.7M, up 16.9%. Imaging momentum was driven by advanced modalities, with same-center advanced imaging volumes up 9.6% in Q4 ...
- Q4 2025 was RadNet's strongest quarter ever: revenue $547.7M, up 14.8%, and Adjusted EBITDA $87.7M, up 16.9%.
- Digital Health revenue for Q4 rose 48.2% to $27.9M, with Digital Health Adjusted EBITDA up 8.9% to $4.9M.
- RadNet completed acquisition of Gleamer, a Paris-based radiology AI company, for up to EUR 230M, inclusive of post-closing milestones.
- +12 more takeaways
EchoStar Fourth Quarter 2025 Earnings Call - Spectrum-sale proceeds and SpaceX equity loom, but tower litigation and $5-7B decommission/tax cash hit cloud outlook
EchoStar is perched between a potential cash windfall from a pending spectrum sale and an opaque equity position in SpaceX, while legacy wireless obligations and active litigation with tower companies...
- EchoStar filed its Form 10-K on March 2, 2026, and reiterated that forward-looking comments are subject to SEC safe-harbor caveats.
- EchoStar Capital is awaiting regulatory approvals for a spectrum sale expected to bring a significant influx of capital during H1 2026, but will not allocate funds until closing.
- Capital deployment priorities under consideration include paying down expensive or maturing debt, managing tax liabilities, evaluating investments at EchoStar Capital, and returning capital to shareholders, with choices to be driven by net shareholder return.
- +12 more takeaways
NextDecade Corporation Q4 2025 Earnings Call - Trains 4 and 5 FID funded; early cargo sales blunt market exposure
NextDecade used 2025 to lock down commercial contracts, secure FIDs for trains 4 and 5, and fund the equity with a back-leveraging structure that preserves common shares. Phase 1 construction is track...
- NextDecade achieved FIDs on trains 4 and 5 in September and October 2025 and fully funded each train using approximately 60% debt and 40% equity at FID.
- NextDecade funded its NextDecade-level equity commitments (~$2.4 billion) through roughly $2.7 billion in term loans plus over $200 million of cash, using a back-leveraging approach (Super FinCo and FinCo facilities) designed to avoid material dilution to common shares.
- Commercial progress: five 20-year SPAs totaling 7.2 MTPA were executed in 2025 (TotalEnergies, Aramco, JERA, EQT, ConocoPhillips), adding to the 1.9 MTPA SPA with ADNOC from 2024, for 9.1 MTPA of SPAs on trains 4 and 5 with fixed liquefaction fees of about $1.2 billion annually before escalation.
- +11 more takeaways
ADT Q4 2025 Earnings Call - Origin AI acquisition positions ADT to shift from reactive alarms to proactive AI sensing
ADT delivered a steady 2025 with results inside guidance, strong cash generation, and an aggressive capital-return stance, but management paints 2026 as a deliberate transition year. The company is in...
- ADT reported full-year 2025 revenue of $5.1 billion, up 5%, and adjusted EBITDA of $2.68 billion, up 4%.
- Adjusted EPS rose 19% to $0.89 per share in 2025, helped by EBITDA growth and lower share count.
- Adjusted free cash flow, including swaps, grew 16% in 2025 and has more than doubled since 2021; ADT returned nearly $800 million to shareholders in 2025 (about $600 million buybacks, $187 million dividends).
- +12 more takeaways
UroGen Pharma Full Year 2025 Earnings Call - Permanent J-code accelerates Zusduri launch; >$1B peak potential
UroGen framed 2025 as a launch year and 2026 as the proof point. Zusduri recorded $15.8 million in 2025 and, with a permanent J-code effective January 1, 2026, management reports clear early accelerat...
- Permanent J-code for Zusduri went into effect January 1, 2026, and management reports a visible step-up in adoption and utilization in early 2026.
- Zusduri net product revenue was $15.8 million in 2025, reflecting an early foundational launch during the miscellaneous J-code period.
- Jelmyto net product revenue was $94 million in 2025; total company revenue was $109.8 million, up 21% year-over-year from $90.4 million in 2024.
- +11 more takeaways
SQM Q4 2025 Earnings Call - Nova Andino Hits Record Lithium Volumes as Prices Inflect Higher
SQM closed 2025 with a clear operational pivot: the newly formed Nova Andino Litio JV with Codelco is running at capacity and delivered record quarterly lithium sales, while realized lithium prices in...
- SQM reported full-year 2025 revenues of $44.6 billion and net income of $588 million.
- SQM and Codelco formalized the Nova Andino Litio JV, enabling long-term lithium production from Salar de Atacama; Nova Andino is running at full capacity.
- Nova Andino sold over 66,000 metric tons of lithium in Q4 2025, more than 50% year-over-year growth and a quarterly record.
- +12 more takeaways
StealthGas Inc. Fourth Quarter 2025 Earnings Call - Debt-Free Balance Sheet, Strong Profits Despite Idle MGC
StealthGas closed 2025 with one of its strongest financial pictures in years, reporting adjusted annual net income of about $65.6 million and achieving a debt-free balance sheet after $350 million of ...
- StealthGas reported adjusted net income of $65.6 million for 2025, the second highest in company history, and adjusted quarterly net income of $13.3 million for Q4 2025.
- Q4 2025 revenues were $39.4 million, down 9.4% year on year; full-year revenues were $173.0 million, up 3.5% YoY.
- The company completed strategic deleveraging in 2025, repaying $86 million that year and $350 million since 2023, and entered 2026 with zero bank debt on the consolidated fleet.
- +14 more takeaways
Venture Global LNG Q4 2025 Earnings Call - Rapid scale-up clears path to $5.2B-$5.8B 2026 EBITDA
Venture Global used Q4 to turn promises into production. The company has quickly moved from IPO to large scale output, nearly tripling revenue and EBITDA year over year, while simultaneously building ...
- Venture Global went public in January 2025 and quickly commercialized assets, with Calcasieu Pass reaching commercial operations in April 2025.
- Q4 2025 revenue was $4.4 billion, up from $1.5 billion in Q4 2024; full year 2025 revenue was $13.8 billion versus $5.0 billion in 2024.
- Consolidated Adjusted EBITDA in Q4 2025 was $2.0 billion, a 191% increase from $688 million in Q4 2024; full year 2025 Consolidated Adjusted EBITDA was $6.3 billion.
- +17 more takeaways
Zymeworks Q4 2025 Earnings Call - Zanidatamab clinical win pushes Ziihera toward potential approval while $250M royalty note fuels buybacks and BD optionality
Zymeworks leaned into a watershed clinical moment and a creative financing move this quarter. Partners Jazz and BeiGene presented HERIZON-GEA-01 data showing zanidatamab combinations produced a median...
- HERIZON-GEA-01 data presented by partners Jazz and BeiGene showed zanidatamab plus chemotherapy, with or without a checkpoint inhibitor, achieved median PFS > 1 year and median overall survival > 2 years in first-line HER2-positive metastatic or locally advanced GEA.
- Jazz expects to submit a supplemental BLA under the FDA Real-Time Oncology Review program in Q1 2026 and anticipates potential approval and launch of zanidatamab (Ziihera) in GEA in H2 2026, subject to FDA review; an additional interim median OS analysis is expected by mid-2026.
- Zanidatamab has Breakthrough Therapy designation for HER2-positive GEA and the HERIZON-GEA-01 benefit was consistent across clinically relevant subgroups, irrespective of PD-L1 exploratory results.
- +12 more takeaways
AAON, Inc. Q4 2025 Earnings Call - BASX Demand Surges to $1.3B Backlog, Margins Hit by Ramping and ERP Headwinds
AAON closed 2025 on clear top-line strength, driven by an accelerating BASX data center business and a resilient AAON branded commercial segment. BASX bookings and backlog exploded, but the company pa...
- BASX momentum is real: full-year BASX branded sales rose 143% to $548 million, and BASX backlog reached $1.3 billion, up 141% year-over-year and 45% sequentially.
- BASX book-to-bill was 2.4 for 2025, signaling strong order intake versus current production capacity.
- Q4 net sales were $424.2 million, up 42.5% year-over-year; BASX Q4 sales grew 109.1% to $106.1 million, AAON branded Q4 sales rose 9.5%.
- +12 more takeaways